The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
AACR 2023 | Choosing the best BTK inhibitor for managing CLL
Kerry Rogers, MD, The Ohio State University, Columbus, OH, comments on the rationale behind choosing certain BTK inhibitors to treat chronic lymphocytic leukemia (CLL). There are currently three covalent BTK inhibitors (ibrutinib, acalabrutinib, and zanubrutinib), and multiple studies comparing the inhibitors. In the case of the ALPINE trial (NCT03734016), zanubrutinib was preferred over ibrutinib, especially when considering adverse events, where ibrutinib increases the risk of atrial fibrillation, ventricular arrhythmia and hypertension. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
